Medivir

Medivir’s partner GSK initiates OTC launch of Xerclear® in Europe under trade na...

2/8/2012 2:30 AM EST

Huddinge - Medivir AB (OMX: MVIR), the research-based specialty pharmaceutical company focused on infectious diseases, announces that its unique cold sore product Xerclear®, which Medivir developed in-house, is now being launched for over-the-counter (OTC) use by its partner GlaxoSmithKline (GSK) in Europe. Xerclear® will be marketed under the trade name Zoviduo and Zovirax Duo in Europe.

In June 2010, Medivir...

Medivir - TMC435 will be evaluated in a phase II combination study with daclatas...

12/2/2011 7:30 AM EST

Huddinge, Sweden - Medivir AB (OMX:MVIR), the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, announces that its development partner, Tibotec Pharmaceuticals, has entered into an agreement with Bristol-Myers Squibb Company (NYSE:BMY).

TMC435, a once daily NS3/4A protease inhibitor (PI) for the treatment of genotype-1 chronic hepatitis C...

Key news from the ongoing Capital Markets Day

11/15/2011 8:45 AM EST

Medivir AB (OMX: MVIR), a research-based speciality pharmaceutical company focused on infectious diseases, reports the following key news concerning their hepatitis C projects.

Medivir programmes in collaboration with Tibotec Pharmaceuticals
Medivir and Tibotec Pharmaceuticals have two programmes for the development of antiviral therapies for future treatment of hepatitis C (HCV), these are based on the HCV...

Medivir’s partner Tibotec announced that final SVR24 results from phase IIb PILL...

11/7/2011 2:45 AM EST

Huddinge, Sweden - Medivir AB (OMX:MVIR), the research-based specialty pharmaceutical company focused on the development of high-value treatments for infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, has announced that safety and efficacy results from the phase IIb PILLAR study of once-daily TMC435 in treatment-naïve patients infected with hepatitis C will be presented as an oral...

Medivir Announces Final Results from TMC435 Phase IIb ASPIRE (C206) Study

11/2/2011 8:30 AM EST

TMC435-Based Therapy Significantly Improved Viral Cure Rates in Patients Who Failed Prior Treatment for Hepatitis C
- ASPIRE: All TMC435 subgroups achieved substantially higher viral cure rates (SVR24) compared with control group (pegylated interferon and ribavirin alone): 85% vs. 37% in prior relapsers, 75% vs. 9% in prior partial responders and 51% vs. 19% in prior null responders –

- Once daily TMC435 was...

Interim Report, 1 January – 30 September 2011

10/24/2011 2:30 AM EST

Operating profit/loss of SEK 156.0 m
Huddinge, Sweden—Today, Medivir AB (OMX: MVIR), a research-based specialty pharmaceutical company focused on infectious diseases, is publishing its Interim Report for the period 1 January – 30 September and its operational report for the third quarter of 2011.

Unless otherwise stated all figures are for the group and comparisons in this Interim Report are with the...

Medivir Announces Acceptance of Four TMC435 Abstracts for Presentation at the AA...

9/30/2011 10:30 AM EST

~ Including a Late-breaking Oral Presentation of final analysis of the TMC435 phase 2b PILLAR study ~
Medivir AB (OMX: MVIR), a research-based speciality pharmaceutical company focused on infectious diseases, today announces that four abstracts related to its once daily (QD), oral investigational hepatitis C drug TMC435 have been accepted for presentation at the Annual Meeting of the American Association for...

Number of shares and votes in Medivir

9/30/2011 2:00 AM EST

The number of shares and votes in Medivir has changed as a result of the exercise of employee stock options.

Today, the last trading day of the month, there are in total 31,253,827 shares and 37,193,827 votes in the company.

Huddinge, September 30, 2011
Medivir AB (publ)

Medivir is required under the Financial Instruments Trading Act to make the information in this press release public. The information was...

Maris Hartmanis appointed new CEO of Medivir

9/26/2011 2:30 AM EST

Huddinge, Sweden – Medivir AB (OMX: MVIR), an emerging research-based specialty pharmaceutical company focused on infectious diseases, today announces that the board has appointed Maris Hartmanis as new President and CEO.

Maris Hartmanis replaces Ron Long, who has been President and CEO of Medivir since 2009. Under Ron Long’s leadership, the company has obtained a clear commercial focus and has taken several...

Completed Enrollment of Three Global Phase 3 Trials for TMC435 in Chronic Hepati...

8/31/2011 7:00 AM EST

Huddinge, Sweden – MedivirAB (OMX: MVIR) is an emerging researchbased specialty pharmaceutical company focused on infectious diseases.

Medivir today announced that its investigational protease inhibitor TMC435, developed by Tibotec Pharmaceuticals, has successfully completed enrollment of three ongoing global phase 3 trials and further reports that all patients are now on TMC435 or active control treatment. The...

Releases - Medivir

Found press releases